Inaphaea Co-Marketing Agreement

Inaphaea Co

Inaphaea is pleased to confirm the execution of a co-marketing agreement ("Agreement") with the Italian biobanking service provider BioRep S.r.l ("BioRep"), a Sapio Group company, to provide Inaphaea's high throughput drug screening services and Patient Derived Cells ("PDC") to BioRep's network of clients. BioRep will provide backup samples storage and logistic services, in addition to molecular biology services into mainland Europe.

Inaphaea and BioRep will be entitled to a percentage of service or sales royalties on relevant contracts introduced by the respective party. Both companies have also agreed to co-market their respective services.

Andrew Carnegie, Head of Strategic Commercial Development at Inaphaea, commented "This deal with BioRep expands our reach into Europe whilst providing backup storage and disaster management solutions."

Mark Eccleston, CEO of ValiRx, commented "BioRep is an excellent partner as we look to offer our PDC product line into European markets. Their expertise in sample management, characterisation capabilities and access to a broad client base as well as logistics are a great fit for Inaphaea."

Michele Piovella, General Manager at BioRep, commented "BioRep are constantly on the look out for new partners with innovative offerings and the Inaphaea Biobank addresses an unmet need for BioRep to be able to provide its current and future clients with oncology research samples and the relevant PDCs in addition to the well-established storage service. We look forward to a productive partnership and will explore additional areas to work together as we go forward."

BioRep is a Sapio Group company established in Milan in 2003, as the first private Biological Resource Centre in Italy able to provide third parties services for biological material preservation to public and private research institutions, biotech and pharmaceutical companies, with the highest levels of quality and safety.

The main facility, embedded into the Biotechnology Department (DIBIT2) of San Raffaele Hospital, one of the largest Science Parks in Europe, has reached a total storage capacity of more than 9 million samples. The company strengthened its position as a reference player for public, private, national and international research centres, and focused its activities on the collection, the shipment, the processing, the storage and the distribution of biological samples.

This network of services is a key support for all the genetic, neurodegenerative, tumour and rare diseases research studies.